Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Fda symbols : Srne save search
Scilex Holding Company Announces Financing of up to $25 Million to Enhance Commercialization of Three FDA Approved Non-Opioid Pain Management Products
Published: 2023-03-21 (Crawled : 14:20) - biospace.com/
SCLX | $0.984 3.43% 3.31% 550K
|
|
| O: -0.38%
H: 6.19%
C: 3.92%
SRNE | $0.015 -8.85% 140K
|
Health Technology
|
| O: 0.78%
H: 7.24%
C: 5.23%
fda management approved commercialization
Sorrento Therapeutics has Received FDA Clearance to Initiate Clinical Trials with a Next Generation mRNA (STI-1557) Vaccine Against Omicron SARS-CoV-2 Virus
Published: 2022-12-06 (Crawled : 18:00) - biospace.com/
SRNE | $0.015 -8.85% 140K
|
Health Technology
|
| O: 1.68%
H: 0.0%
C: -7.02%
sti-1557 fda clearance trials vaccine mrna virus therapeutics sars-cov-2
Scilex Holding Company, a Sorrento Company, Announces That the FDA Has Granted Fast Track Designation for SP-103 (Lidocaine Topical System) 5.4%, Next Generation Triple Strength Formulation of ZTlido®, for the Treatment of Acute LBP
Published: 2022-08-31 (Crawled : 08:00) - biospace.com/
SRNE | $0.015 -8.85% 140K
|
Health Technology
|
| O: 5.15%
H: 2.94%
C: 0.49%
sp-103 ztlido treatment fda designation granted fast track designation
Scilex Holding Company, a Sorrento Company, Announces That the FDA Has Granted Fast Track Designation for SP-103 (Lidocaine Topical System) 5.4%, Next Generation Triple Strength Formulation of ZTlido®, for the Treatment of Acute Low Back Pain (LBP)
Published: 2022-08-31 (Crawled : 04:00) - globenewswire.com
SRNE | $0.015 -8.85% 140K
|
Health Technology
|
| O: 5.15%
H: 2.94%
C: 0.49%
sp-103 ztlido treatment fda designation back granted fast track designation
Sorrento Therapeutics Announces the FDA IND Clearance of STI-1558, An Oral M(pro) and Cathepsin L Inhibitor to Treat COVID-19
Published: 2022-07-19 (Crawled : 19:00) - globenewswire.com
SRNE | $0.015 -8.85% 140K
|
Health Technology
|
| O: -0.37%
H: 14.02%
C: 6.27%
sti-1558 covid-19 fda clearance therapeutics
Sorrento Announces FDA Authorization to Proceed With Phase 2 Study of Abivertinib (Fujovee™) to Treat Metastatic Castrate Resistant Prostate Cancer (MAVERICK Trial)
Published: 2022-05-17 (Crawled : 17:00) - biospace.com/
SRNE | $0.015 -8.85% 140K
|
Health Technology
|
| O: 4.17%
H: 6.0%
C: 4.67%
fda authorization cancer phase 2 prostate cancer
Sorrento Announces FDA Authorization to Proceed with Phase 1 Study of Intravenous STI-9167 (COVISHIELD), a Potent Neutralization Antibody Against Omicron BA.2 and Other SARS-CoV-2 Variants of Concern
Published: 2022-04-25 (Crawled : 14:00) - globenewswire.com
SRNE | $0.015 -8.85% 140K
|
Health Technology
|
| O: 0.0%
H: 5.26%
C: 2.92%
sti-9167 fda antibody sars-cov-2 authorization phase 1
Sorrento Reports FDA Clearance for the Commencement of a Phase 2/3 Study for Abivertinib in Treatment of Hospitalized Patients With Severe Pneumonia Due to COVID-19
Published: 2022-03-31 (Crawled : 14:00) - biospace.com/
SRNE | $0.015 -8.85% 140K
|
Health Technology
|
| O: 1.27%
H: 0.26%
C: -2.92%
covid-19 treatment fda clearance phase 2
Sorrento Announces FDA Authorization to Proceed With Phase 1 Study Of Intranasal STI-9199 (COVISHIELD), a Potent Neutralization Antibody Against Covid-19 Viruses
Published: 2022-03-02 (Crawled : 18:00) - biospace.com/
SRNE | $0.015 -8.85% 140K
|
Health Technology
|
| O: 1.02%
H: 0.0%
C: 0.0%
sti-9199 covid-19 fda covid phase 1 authorization antibody
Sorrento Therapeutics Announces FDA Clearance of Its IND Application of Next Generation oHSV Oncolytic Virus STI-1386 for Patients With Relapsed and Refractory Solid Tumors
Published: 2021-12-20 (Crawled : 15:30) - biospace.com/
SRNE | $0.015 -8.85% 140K
|
Health Technology
|
| O: -1.46%
H: 1.49%
C: -2.34%
sti-1386 fda clearance solid tumors application therapeutics fda clearance
Sorrento Receives FDA Clearance to Proceed With Clinical Trial for Anti-TROP-2 Antibody Drug Conjugate (TROP-2 ADC) for multiple solid tumors
Published: 2021-10-13 (Crawled : 14:15) - globenewswire.com
SRNE | $0.015 -8.85% 140K
|
Health Technology
|
| O: 2.45%
H: 0.52%
C: -0.15%
fda clearance fda solid tumors antibody drug trial clearance
FDA Authorizes Sorrento Phase 2 Trial of Epidural Resiniferatoxin for the Orphan Indication of Control of Intractable Cancer Pain
Published: 2021-10-13 (Crawled : 13:15) - globenewswire.com
SRNE | $0.015 -8.85% 140K
|
Health Technology
|
| O: 2.45%
H: 0.52%
C: -0.15%
fda phase 2 cancer trial authorized
Sorrento Receives FDA Authorization to Start Phase 1 Clinical Trial of Proprietary, "Off-the-Shelf", Allogeneic anti-CD38 DAR-T (Dimeric Antigen Receptor-T) Cell Therapy to Treat Relapsed or Refractory Multiple Myeloma
Published: 2021-08-02 (Crawled : 14:00) - biospace.com/
SRNE | $0.015 -8.85% 140K
|
Health Technology
|
| O: 1.71%
H: 1.8%
C: -0.12%
fda phase 1 therapy trial authorized t-cell
FDA Clears Sorrento Phase 2 Trial Of Non-Opioid Product Candidate Resiniferatoxin (RTX) For Treatment of the Knee Pain in Osteoarthritis (OA) Patients
Published: 2021-07-06 (Crawled : 19:00) - globenewswire.com
SRNE | $0.015 -8.85% 140K
|
Health Technology
|
| O: -1.05%
H: 1.06%
C: -12.02%
treatment fda phase 2 opioid osteoarthritis trial fda clearance
Sorrento Announces Clinical Research Agreement With Mayo Clinic and FDA Clearance for the First Phase 1b Pilot Study Using Sofusa Lymphatic Drug Delivery Technology to Deliver Ipilimumab in Patients With Melanoma
Published: 2021-06-11 (Crawled : 13:15) - globenewswire.com
SRNE | $0.015 -8.85% 140K
|
Health Technology
|
| O: 0.92%
H: 2.5%
C: 0.68%
fda clearance fda phase 1 drug research technology drug delivery liver phase 1b clearance phase 2b
Sorrento Receives FDA Clearance to Proceed With Phase 2 Study for Sti-3031, an Anti-Pd-L1 Antibody, for Advanced Urothelial Carcinoma
Published: 2021-04-27 (Crawled : 16:00) - globenewswire.com
SRNE | $0.015 -8.85% 140K
|
Health Technology
|
| O: -1.43%
H: 9.54%
C: 6.4%
fda clearance fda phase 2 antibody clearance urothelial carcinoma
Scilex Holding, a Subsidiary of Sorrento, Has Received From FDA a sNDA Approval for ZTlido® Label Expansion
Published: 2021-04-09 (Crawled : 20:00) - globenewswire.com
SRNE | $0.015 -8.85% 140K
|
Health Technology
| Email alert
Add to watchlist
IMAB | $1.81 0.56% 0.55% 200K
|
Health Technology
| Email alert
Add to watchlist
fda expansion approval
Sorrento Receives US FDA Clearance to Proceed With Phase 1 Study for STI-2099 (Intranasal COVIDROPS) in Healthy Volunteers and Outpatient Treatment for Newly Diagnosed COVID-19 Positive Patients
Published: 2021-03-02 (Crawled : 21:04) - globenewswire.com
SRNE | $0.015 -8.85% 140K
|
Health Technology
|
| O: 1.37%
H: 2.41%
C: -5.21%
covid fda clearance treatment fda phase 1 drop positive phase 3 phase 2 clearance
Sorrento Receives FDA Clearance to Start Clinical Trial of Anti-CD47 Antibody, Discovered from Fully Human G-MAB Library, for Treatment of Multiple Malignancies
Published: 2021-03-02 (Crawled : 14:04) - globenewswire.com
SRNE | $0.015 -8.85% 140K
|
Health Technology
|
| O: 3.71%
H: 1.22%
C: -11.19%
fda clearance treatment fda antibody trial anti-cd40 clearance
Sorrento Announces It Has Submitted An Emergency Use Authorization (EUA) Application to the FDA for COVI-STIX™ Rapid Test for the Detection of SARS-CoV-2 Viral Antigen
Published: 2020-12-22 (Crawled : 00:02) - globenewswire.com
SRNE | $0.015 -8.85% 140K
|
Health Technology
|
| O: 6.51%
H: 15.47%
C: 11.31%
fda merge test authorized sars-cov-2 application emergency use authorization
Gainers vs Losers
| 78% | 22% |
Top 10 Gainers
MTTR | News 4 | $4.6 164.37% 62.17% 28M
|
AGBA | $2.94 135.2% 57.48% 66M
|
Finance
EDBL | News | $6.46 71.81% 41.8% 2M
|
MTC | $2.25 44.23% 30.67% 6M
|
Technology Services
OPRT | News | $3.175 41.11% 29.13% 12M
|
Finance
SHIM | $3.05 35.56% 26.23% 1.1M
|
HKIT | $1.345 31.86% 24.16% 390K
|
Technology Services
ABVC | $1.36 30.77% 23.53% 7.4M
|
Wholesale Trade
OST | $0.512 28.0% 21.88% 290K
|
POET | $1.59 27.2% 21.38% 4.2M
|
Manufacturing
Your saved searches
Save your searches and get alerts when important news are released.